CALL TEXT

Fifth transnational call for research projects within the JPIAMR

Comparison of prevention, control and intervention strategies for AMR infections through multidisciplinary studies, including One Health approaches

1. Aim of the call

Specific challenge:

In order to protect and prolong the usefulness of existing antimicrobials, increasing cross-sectoral efforts are needed to rationalize their use and misuse in human and animal health and food production settings. Key measures to achieve this are to improve existing and implement new evidence-based control, prevention, stewardship and intervention strategies to reduce the risk of acquisition, development and transmission of antibiotic-resistant bacteria and infection caused by these pathogens, in hospitalized patients, outpatients, healthy people, animals and the environment.

Despite significant investments in research and increased knowledge about the development, acquisition, occurrence, and transmission pathways of AMR, little of this research has translated into interventions to significantly improve health care by reducing improper antibiotic usage or infections by resistant microbes. Furthermore, much of what has been recommended as interventions to control AMR has been based on experience, empiricism, and common sense, rather than strong evidence. Consequently, the evidence-base for key interventions including detection, screening, isolation, decolonization, environmental decontamination, and antibiotic stewardship remains weak. The lack of sufficient evidence-based research is a problem in veterinary and agriculture science too, which has limited prospects for new antibiotics and therefore, interventions to enable lowering antibiotic usage in animal husbandry are vital.

It is a formidable challenge to decrease the misuse of antibiotics as well as to implement measures to block transmission of AMR in humans and animals. Cultural, contextual and behavioral determinants influence antibiotics use and may also determine interventions which are most cost-effective and/or can be successfully implemented.

In summary, controlled integrated studies between human population, health care systems, and agricultural settings, multiple sectors are urgently needed to devise the optimal intervention strategies across diverse cultural settings and heterogeneous systems of human health and animal health and food production.

Only multinational projects will be funded. Each proposal must involve a minimum of three (3) countries participating in this call and a maximum of six (6) project participants with maximum of one (1) or two (2) participants from each country (see 2.1 Eligibility criteria for further details).

Please note that for countries: **Belgium, Germany, Italy, Latvia and Romania** there may be **only one (1)** participant per project, whereas for **Canada, Ireland, Israel, Netherlands, Norway, Poland, Spain, Sweden and Switzerland** there may be up to **two (2) partners** per project.

1.1 Call Topics:

- One Health oriented pilot studies to determine feasibility and protocols for future large scale multi-center and multi-national studies of different prevention or intervention strategies designed to prevent AMR infections in community, health care, agricultural and environmental settings. The One Health approach is encouraged, but not mandatory.
- Compared effectiveness and economic evaluation of the implementation of new and/or more cost-effective methods for rapid detection and diagnosis of infections by multi-drug resistant microorganisms (MDR) for the purpose of identification of appropriate therapy, transmission routes or early detection of outbreaks in different settings.
- Investigations of efficacy and effectiveness of behavioral intervention strategies, public awareness strategies or other stewardship strategies aiming at reducing the use and misuse of antibiotics and the development and transfer of AMR.
- Assessment of new methods to improve and raise hygiene and sanitation standards to reduce infections in health and care settings.
- Evaluation of the impact of new ways to standardize and utilize antimicrobial use and transmission data on intervention strategies and prevention of antimicrobial resistance.

For all of the above: Special emphasis on low and middle-income countries and a One Health perspective or partnership is encouraged but subject to the scope and mandate of national funding agencies participating in the call (See specific national requirements).

1.2 Expected Impact:

It is expected that through international collaborations that combine complementary and synergistic research strengths, this JPIAMR call will increase the understanding of **prevention, control, stewardship and intervention strategies for AMR infections.** Proposals are expected to clearly define targets and milestones to deliver relevant outcomes within the funding period.

2. Application:

2.1 Eligibility

Applicants must adhere to the specific regulations of the national funding organisations. Each transnational consortium submitting a proposal must involve:

- a minimum of three (3) eligible partners from three (3) different countries participating in the call
- a maximum of six (6) project partners. However, consortia including partners from Latvia, Poland or Romania may increase the total number of partners to seven (7), in order to increase representation of these countries in JPI AMR projects.
- **a maximum of one or two partners from a participating country per project** (please see above and national eligibility criteria).

- Project participants not eligible to be funded (e.g. from non-funding countries or not fundable according to national/regional regulations of the participating funding countries) may be involved in projects if they secure their own funding and if their expertise is indispensable for reaching the objectives. However, **the maximum number of six (6) participants may not be exceeded**, unless partners from Latvia, Poland or Romania are included.
- The consortia should always consist of a majority of funded project participants. The budget of a non-funded partner shall not exceed 30% of total transnational project budget requested.
- Project participants not eligible to be funded cannot be consortium coordinators and must accept all JPIAMR rules and guidelines just as funded members.

Project duration may be max 36 months.

2.2 Submission of joint transnational proposal

Submissions of proposals will be in two steps. In both cases, one joint proposal document (in English, and following the provided template) shall be prepared by the project participants of a joint transnational proposal, and must be submitted to the Joint Call Secretariat by the coordinator. A submission tool will be implemented in the JPIAMR website.

The two-steps application process (pre-proposal, full proposal) will have the following timetable:

January 18th, 2017	**Publication of the JPIAMR ERA-NET 2017 Call**
March 21st, 2017 (17:00 CET)	**Submission deadline for pre-proposals**
Mid May 2017	**Full proposal invitations send to project coordinators**
July 4th, 2017 (17:00 CET)	**Submission deadline for full proposals**
October/November 2017	**Final funding decision announced to applicants**[1]
End of 2017/Early 2018	**Start of funding**

2.3 Financial modalities and funding prerequisites

Funding is granted for a maximum of three years in accordance with national regulations. **Applicants must refer and adhere to their own specific national regulations and scientific remits as detailed in the National and Regional Requirements (see Annex B).**

The funds provided by the Parties are listed in the table below. The "virtual common pot model" shall apply for this transnational call. As such, each country will fund its own approved project partners. The proposals will be funded following the ranking list recommended by the Peer Review Panel.

[1] Due to administrative and legal regulations, the National Institute of Health Carlos III declares the 22nd of September of 2017 as national deadline for the decision on fundable projects. Any ISCIII applicant in an proposal for which no final decision has been made, will be declared not fundable.

Anticipated funding provided by each party

Country	***Name of Organisation***		***Contribution***
Belgium	Fonds voor Wetenschappelijk Onderzoek-Vlaanderen	FWO	€ 0.2 M
Canada	Canadian Institutes of Health Research	CIHR	CAD 3 M
Germany	Bundesministerium für Bildung und Forschung (BMBF) / Deutsches Zentrum für Luft- und Raumfahrt (DLR)	BMBF/DLR	€ 3 M
Ireland	Health Research Board	HRB	€ 0.37 M
Israel	Chief Scientist Office, Ministry of Health	CSO-MOH	€ 0.5 M
Italy	Ministry of Health	IT-MOH	€ 0.4 M
Latvia	Valsts izglītības attīstības aģentūra	VIAA	€ 0.21 M
Netherlands	Zorgonderzoek Nederland	ZON	€ 1 M
Norway	The Research Council of Norway	RCN	€ 1.5 M
Poland	Narodowe Centrum Nauki	NCN	€ 0.5 M
Romania	National Authority for Scientific Research and Innovation	ANCSI	€ 0.25 M
Spain	National Institue of Health Carlos III	ISCIII	€ 0.15 M
Sweden	Swedish Research Council	SRC	€ 1.5 M
Switzerland	Swiss National Science Foundation	SNSF	€ 0.6 M

Each funded consortium should provide a consortium agreement (CA) signed by all participants. The project consortium is strongly encouraged to sign this CA before the start of the project to clarify the potential IPR matters (such as licensing in, licensing out, patent and exploitation strategy), and in any case no later than six months after the official project start date. The points that must be addressed in the CA are detailed in the Annex C.

2.4 Contact persons

The only official communication line of the proposal is between the Joint Call Secretariat and the project coordinator. The project coordinator will be the person contacted by the Joint Call Secretariat during the application procedure, so he/she must forward this information to other participants. Each funding organization has national contact persons who can be contacted for information about the specific national requirements (see Annex A).

Please note that country specific requirements might apply to this call. Compliance with the national/regional regulations specified in the country specific information is mandatory (See Annex B). We strongly advise you to contact your national/regional representative prior to submitting a pre-proposal.

3. Evaluation

Pre-proposals and full proposals will be assessed according to specific evaluation criteria (see below), using a common evaluation form. A scoring system from 0 to 5 will be used to evaluate the proposal's performance with respect to the different evaluation criteria.

Scoring system:

0: Failure. The proposal fails to address the criterion in question, or cannot be judged because of missing or incomplete information.

1: Poor. The proposal shows serious weaknesses in relation to the criterion in question.

2: Fair. The proposal generally addresses the criterion, but there are significant weaknesses that need corrections.

3: Good. The proposal addresses the criterion in question well but certain improvements are necessary.

4: Very good. The proposal addresses the criterion very well, but small improvements are possible.

5: Excellent. The proposal successfully addresses all aspects of the criterion in question.

Evaluation criteria:

1. **Excellence**
   a. Clarity and pertinence of the objectives
   b. Credibility of the proposed approach and methodology
   c. Soundness of the concept
   d. Innovative potential
   e. Competence and experience of participating research partners in the field(s) of the proposal (previous work in the field, specific technical expertise

2. **Impact**
   a. Potential of the expected results for future clinical, public health and/or other socio-economic health relevant applications including patients' needs
   b. Added-value of transnational collaboration: gathering a critical mass of patients/biological material, sharing of resources (models, databases, diagnosis etc.), harmonization of data, sharing of specific know-how and/or innovative technologies.
   c. Effectiveness of the proposed measures to exploit and disseminate the project results (including management of IPR), to communicate the project, and to manage research data where relevant
   d. Industry and Patient Organization participation/engagement (when appropriate/applicable)

3. **Quality and efficiency of the implementation**
   a. Coherence and effectiveness of the work plan, including appropriateness of the allocation of tasks, resources and time-frame
   b. Complementarity of the participants within the consortium
   c. Appropriateness of the management structures and procedures, including risk and innovation management
   d. Concept for sustainability of infrastructures initiated by the project
   e. Budget and cost-effectiveness of the project (rational distribution of resources in relation to project's activities, partners responsibilities and time frame)

Sub-criteria 2a and 2b will be prioritized for assessing the impact of proposals (pre- and full proposal stage).

Evaluation scores will be awarded for the 3 main criteria, and not singularly for the different aspects listed below the criteria. The threshold for individual criteria will be 3. The maximum score that can be reached from all three criteria together is 15 points.

If two projects receive the same final score and the same score for excellence, a project including a partner from Latvia, Poland or Romania should have a priority in considering for funding.

4. Reporting requirements and other obligations of JPIAMR grantees

Each partner will be funded through national grants from their respective funding agency. National reporting requirements apply according to the national rules of each specific country (See Country-specific information).

In addition, grantees have an obligation to submit progress and final scientific reports to the JPIAMR Joint Call Secretariat according to "JPIAMR Guidelines for Applicants and Grant Holders" and supply the JPIAMR with updated information of the consortium and its results for promotion of the call.
All dissemination of results from the funded projects should acknowledge funding from the JPIAMR. Coordinators are expected to participate in and contribute to JPIAMR workshops and other events associated with this call.
For more information please see "JPI AMR Guidelines for Applicants and Grant Holders" (www.jpiamr.eu).

Annex A: National contact persons for each party providing funding

Country	*Funding org.*	*Contact person(s)*	*Email*
Belgium	FWO	Olivier Boehme Toon Monbaliu	eranet@fwo.be
Canada	CIHR	Olivier Jacob-Gravel Élisabeth Pagé	olivier.jacob-gravel@cihr-irsc.gc.ca elisabeth.page@crchudequebec.ulaval.ca
Germany	BMBF/DLR	Dr. Barbara Junker Dr. Akin Akkoyun	barbara.junker@dlr.de akin.akkoyun@dlr.de
Ireland	HRB	Ellen Moran	emoran@hrb.ie
Israel	CSO-MOH	Ahmi Ben-Yehudah Ayelet Zamir	ahmi.by@moh.gov.il ayelet.zamir@moh.gov.il
Italy	IT-MOH	Dr. Raffaele Ruocco Dr. Maria Jose Ruiz	research.EU.dgric@sanita.it mj.ruizalvarez-esterno@sanita.it
Latvia	VIAA	Dr Maija Bundule Dr Uldis Berkis	Maija.Bundule@viaa.gov.lv Uldis.Berkis@viaa.gov.lv
Netherlands	ZON	Thera Habben Jansen	HabbenJansen@zonmw.nl
Norway	RCN	Sonja Prehn Dyveke Hetland	sp@rcn.no dhe@rcn.no
Poland	NCN	Jerzy Fraczek Malwina Gębalska	jerzy.fraczek@ncn.gov.pl malwina.gebalska@ncn.gov.pl
Romania	ANCSI	Ioana Ispas	ioana.ispas@ancs.ro
Spain	ISCIII	Irene Sánchez	isanchezgarcia@isciii.es
Sweden	SRC	Anh Thu Nguyen Hoang Patriq Fagerstedt	anhthu.nguyenhoang@vr.se patriq.fagerstedt@vr.se
Switzerland	SNSF	Barbara Flückiger	barbara.flueckiger@snf.ch

Annex B: Specific National and Regional Requirements

Belgium – FWO

Funding of industrial partners	No
Participation of industry required?	No
Maximum funding	200.000 EUR /1 project/ 3 years
Eligible costs	Funding money can be used for staff, consumables and infrastructure. The minimal and maximal amounts of money allowed per cost category, as applicable for the regular FWO-projects, are not applicable for the projects funded by FWO in ERA-NET. Overhead is not an eligible cost. Notwithstanding, FWO pays the host institutions of a project 6% overhead on top of the funding amount.
Additional documents required	No
Other national restrictions	See national regulations

Canada CIHR

Funding of industrial partners	No
Participation of industry required?	No
Maximum funding	CIHR will contribute as followed per year per application. 1 Canadian participant in the consortium: up to $200,000 2 Canadian participants in the consortium: up to $250,000 (for the team) 1 Canadian coordinator in the consortium: up to $250,000 1 Canadian coordinator + 1 Canadian participant in the consortium: up to $300,000 (for the team)
Eligible costs	Recipients should review the Use of Grant Funds section of the Tri-Agency (CIHR, NSERC and SSHRC) Financial Administration Guide for a complete listing and description of allowable costs and activities.
Additional documents required	Canadian applicants invited to submit a full application must complete a CIHR application and submit it using ResearchNet. The deadline for submission of this application is the same as the Full Application deadline to Joint Action Secretariat. The purpose of this additional application to CIHR is to provide CIHR with an Operating Budget for the project, with the amounts quoted in Canadian dollars.
Other national restrictions	The Nominated Principal Applicant (NPA) must be an independent Researcher. The NPA must have an academic or research appointment at a CIHR eligible institution (See Institutional Eligibility Requirements for eligibility process and associated timelines. No indirect costs will be covered.

Germany BMBF/DLR

Funding of industrial partners	Yes
Participation of industry required?	No
Maximum funding	Max. 300.000 EUR per project
Eligible costs	See national guidelines
Additional documents required	No
Other national restrictions	See national guidelines

Ireland

Funding of industrial partners	No
Participation of industry required?	No
Maximum funding	370,000K in total (inclusive of overheads and pension contributions) – One project will be funded.
Eligible costs	Salary related costs, small equipment costs, travel, direct running costs, dissemination and knowledge exchange costs, overheads (in accordance with the HRB Policy on Overhead Usage, the HRB will contribute to the indirect costs of the research through an overhead payment of 30% of Total Direct Modified Costs (TDMC excludes student fees, equipment and capital building costs) for **laboratory or clinically-based research** and 25% of Total Direct Costs if **desk-based research.**
Additional documents required	Applicants from Ireland in consortia invited to submit a full application will be required to provide additional information to the HRB at the time of the full application submission deadline. This will include justification for their requested budget, and clarification on deliverables assigned to the partner from Ireland. A template requesting the information required from applicants from Ireland will be provided by the HRB.
Other national restrictions	Proposals from Irish institutions that include human Embryonic Stem Cell Research will be deemed **ineligible.**

Israel CSO-MOH

Funding of industrial partners	Only on their own funding
Participation of industry required?	No
Maximum funding	Up to 160,000 euros per project. Israeli coordinator may ask for an additional 10,000 euros
Eligible costs	Personnel (students, technicians, applicants excluded); Animals, Materials and consumables; Travel (up to 10%); Institutional overhead 10%. No permanent equipment.

Additional documents required	Prior to submission, researchers will submit to CSO-MOH an abstract approved by their research authority including detailed budget distribution. This abstract describes their work in the consortium. It is not the consortium submitted abstract. No submission of abstract can lead to disqualification of the whole application, as well as the consortium.
Other national restrictions	Research will not be funded simultaneously by CSO-MOH on more than one grant (ERA-NET or national). Researchers can only apply for one grant from any ERA-NET funded by CSO-MOH or submit only one proposal for any single programme. Please see detailed instructions at www.health.gov.il/research-fund reports will be submitted annually to CSO-MOH.

Italy IT-MOH

Funding of industrial partners eligible?	Only Scientific Institutes for Research, Hospitalization and Health Care(Istitutidi Ricoveroe Curaa Carattere Scientifico pubblicie privati, IRCCS)are eligible. No industrial partners are eligible.
Participation of industry required?	No
Maximum funding	Max 250.000 € per project
Eligible costs	Only costs generated during the lifetime of the project can be eligible. Personnel (only ad hoc contracts/consultants/fellowship, max 50% of the requested fund); travel costs and subsistence allowances (max 10% of the requested fund); equipment (rent/leasing only, no limit), consumables (no limit), dissemination of results (publications, meetings/workshops etc.- max 1% of the requested fund); data handling and analysis (no limit); overhead (maximum 10% of the requested fund). (All according to the national regulations). Travel expenses and subsistence allowances associated with training activities only linked to the project
Additional documents required	The simultaneous participation in proposals submitted to different transnational research calls, funded by the Ministero della Salute, is not allowed to Italian Principal Investigators or other research team members. In order to expedite the eligibility check process, the Ministry of Health will grant an eligibility clearance to the applicants prior to the submission of the pre-proposals. To this end, it is mandatory that the applicants fill out and return a pre-eligibility (Italy_MOH_mandatory_pre-eligibility check form 2017) check form trough IRCCS Scientific Directorate or Regional Office Health Research using WFR System 10 days before submitting their pre-proposals to the Joint Call Secretariat. It is strongly recommended that the form, completed and duly signed, is returned at least 10 working days before the pre-proposal submission deadline. Applicants will be sent a written notification of their eligibility status.

Other national restrictions	After the JPI-AMR JTC 2017 peer review has been completed and the final (scientific) ranking list has been performed and endorsed by the Call Steering Committee, the Ministry of Health will invite the principal investigators of the projects approved for funding to enter the formal national negotiations (according to national regulations). The funding of this projects are under the Ricerca Corrente IRCCS rules.

Latvia VIAA

Funding of industrial partners eligible?	1. Funding of industrial partners is eligible only if they represent enterprises entered into the Latvian Commercial registry, assumed they are eligible to do the specific research and are in possession of necessary resources in Latvia. The main activity of such an enterprise, also scientific activity, should be in Latvia. Limitations of EU legislation apply (R651/2014) together with financial reporting and audit requirements. 2. The other category of partner eligible for funding by VIAA is Research institutions: Universities, research institutes, other research institutions - must be listed in the Latvian register of scientific institutions. Must comply with Research and knowledge-dissemination organization criteria (R651/2014). Any other type of participants is not covered by VIAA mandate.
Participation of industry	No
Maximum funding	Per partner: 70.000 EUR/year, i.e. maximum grant per partner 210.000 EUR for a 3-year project.
Eligible costs	• Personnel incl. social tax (maximum rates apply) • Consumables • Animals • Subcontracts (up to 25%) needs detailed justification, subject to approval. Includes all external services. • Equipment (only depreciation costs) • Replaceable un fully consumable during project elements of equipment e.g. electrodes fully • Travel (according to travel plan) • Indirect costs (up to 25% of direct costs exempt subcontracting)
Additional documents required	Applicants might be asked to provide additional information in order to assess their eligibility. Applicants are obliged to provide any information specified by Provisions of the Cabinet of ministers No 259, 26.05.2015 upon request.

Other national restrictions	See Provisions of the Cabinet of Ministers: http://likumi.lv/ta/id/274671-atbalsta-pieskirsanas-kartiba- dalibai-starptautiskas-sadarbibas-programmas-petniecibas-un- tehnologiju-joma They should be followed without any exception. All limits and conditions contained in the Provisions in relation to ERA-NET or ERA-NET Cofund are an eligibility criteria for funding

Netherlands ZON

Funding of industrial partners eligible?	Please consult http://www.zonmw.nl/nl/subsidies/voorwaarden-
Participation of industry required?	No
Maximum funding	1 Dutch participant in the consortium: max €300.000 2 Dutch participants in the consortium: max €450.000 (for the both of them together) 1 Dutch coordinator in the consortium: max €350.000 1 Dutch coordinator + 1 Dutch participant in the consortium: max € 500.000 (for the both of them together)
Eligible costs	Please consult http://www.zonmw.nl/nl/subsidies/voorwaarden-
Additional documents required	Please consult http://www.zonmw.nl/nl/subsidies/voorwaarden-
Other national restrictions	Please consult http://www.zonmw.nl/nl/subsidies/voorwaarden- en-financien/ or your national contact person

Norway RCN

Funding of industrial partners	Yes
Participation of industry required?	No
Maximum funding	0,7 M€ for the total 3 year period
Eligible costs	1,5 M€ for the total 3 year period
Additional documents required	No
Other national restrictions	See national guidelines. Please note that you can only be the Project manager for one project in this call. However you can be partner on several applications

Poland NCN

Funding of industrial partners	Yes
Participation of industry required?	No
Maximum funding	NCN call budget: EUR 500 000
Eligible costs	Please see UNISONO: https://ncn.gov.pl/sites/default/files/pliki/uchwaly-rady/2016/uchwala114_2016-zal1.pdf (p. 6-13). **Overhead costs** must not exceed a maximum of **40%** of the total eligible costs (excl. equipment) and may not be increased during the course of a research project.

Additional documents required	On the full proposal stage Polish applicants must register their applications in the OSF submission system (UNISONO application). This application includes the following budgettable: http://ncn.gov.pl/sites/default/files/pliki/UNISONO_budget_table.xlsx.
Other national restrictions	**Who can apply**? Any researcher, with a **doctoral degree**, employed at a Polish institution may act as a Principal Investigator. **Project duration**: 24 or 36 months Only proposals involving **basic research** (original experimental or theoretical research work undertaken primarily to acquire new knowledge of the underlying foundations of phenomena and observable facts) may be submitted in response to the call for proposals. If one international project includes partners from **two different Polish Host Institutions**, these institutions must apply as a **consortium**. Each Host Institution comprising the consortium has a separate budget, but the limit on the remuneration applies to the consortium as a whole (UNISONO, p. 9-10) . Applicants are obliged to adhere to the rules included in the following document (UNISONO): https://ncn.gov.pl/sites/default/files/pliki/uchwaly-rady/2016/uchwala114_2016-zal1.pdf.

Romania ANCSI

Funding of industrial partners	No
Participation of industry required?	No
Maximum funding	Up to 200.000 EUR/partner Up to 250.000 EUR/coordinator
Eligible costs	See national guidelines http://uefiscdi.gov.ro/articole/4271/Dezbatere-publica-pachet- informatii-proiecte-ERA-NET-ERA-NET-
Additional documents required	No
Other national restrictions	See national guidelines http://uefiscdi.gov.ro/articole/4271/Dezbatere-publica-pachet- informatii-proiecte-ERA-NET-ERA-NET-Cofund.html

Spain ISCIII

Funding of industrial partners	No
Participation of industry required?	No
Maximum funding	150.000
Eligible costs	See: ISCIII National Annex
Additional documents required	No
Other national restrictions	See: ISCIII National Annex

Sweden SRC

Funding of industrial partners	No
Participation of industry required?	No
Maximum funding	Max. 300.000 EUR per project (1 Swedish participant in the in the consortium: max € 300.000, 2 Swedish participants in the consortium: max € 300.000 for the both of them together).
Eligible costs	The same as for applications for SRC project grants
Additional documents required	No
Other national restrictions	See national guidelines: http://www.vr.se/inenglish/researchfunding/applyforgrants/conditionsforapplicationsandgrants.4.5adac704126af4b4be280007743.html

Switzerland SNSF

Funding of industrial partners	No
Participation of industry required?	No
Maximum funding	No
Eligible costs	See regular SNSF guidelines
Additional documents required	No
Other national restrictions	Projects must fit with the goals of the National Research Programme “Antimicrobial Resistance” (NRP 72): www.nrp72.ch

Annex C: Guidelines for Consortium Agreement for Project Participants

Each consortium should provide a Consortium Agreement (CA) signed by all participants before the start of the project to clarify the potential IPR matters (such as licensing in, licensing out, and patent and exploitation strategy). The CA must address (as a minimum), the following points:

- common start date and duration of the research project
- organisation and management of the project
- role and responsibilities of each partner, resources and funding
- confidentiality and publishing
- Intellectual Property Rights
- decision making within the consortium
- handling of internal disputes
- the liabilities of the research partners towards one another (including the handling of default of contract).

Any issues regarding funding are a bilateral matter between each project partner and the relevant funding organisation and should be excluded from the CA. The CA together with any other information required by national/regional regulations must be made available on request to the national funding agencies.